Lunai Bioworks (STU:2Q5) Beneish M-Score: 0.00 (As of Jul. 29, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:2Q5 Lunai Bioworks Inc STU:2Q5
26 GF Score
Price €8.37
! 6 Warning Signs
View Full Analysis

What is Lunai Bioworks Beneish M-Score?

Lunai Bioworks STU:2Q5 26 Beneish M-Score is 0.00 as of Jul. 29, 2026. GuruFocus rates STU:2Q5 with a GF Score™ of 26/100. The stock has 6 warning signs investors should review. Among 824 Biotechnology companies, Lunai Bioworks ranks worse than 121359.1% on this metric.

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

The historical rank and industry rank for Lunai Bioworks's Beneish M-Score or its related term are showing as below:

During the past 13 years, the highest Beneish M-Score of Lunai Bioworks was 0.00. The lowest was 0.00. And the median was 0.00.

Lunai Bioworks Beneish M-Score Historical Data

* Premium members only.

The historical data trend for Lunai Bioworks's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Lunai Bioworks Beneish M-Score Chart

Lunai Bioworks Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
Beneish M-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Lunai Bioworks Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Beneish M-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

STU:2Q5 vs BCLI, BIVI, XCUR: Beneish M-Score Comparison

For the Biotechnology subindustry, Lunai Bioworks's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Lunai Bioworks Beneish M-Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Lunai Bioworks's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where Lunai Bioworks's Beneish M-Score falls into.


STU:2Q5
26GF Score
Lunai Bioworks Inc STU:2Q5
Beneish M-Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Lunai Bioworks Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of Lunai Bioworks for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * +0.528 * +0.404 * +0.892 * +0.115 *
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * +4.679 * -0.327 *
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Mar26) TTM:Last Year (Mar25) TTM:
Total Receivables was €0.00 Mil.
Revenue was 0.018 + 0 + 0 + 0 = €0.02 Mil.
Gross Profit was 0.018 + 0 + 0 + 0 = €0.02 Mil.
Total Current Assets was €3.23 Mil.
Total Assets was €8.53 Mil.
Property, Plant and Equipment(Net PPE) was €0.01 Mil.
Depreciation, Depletion and Amortization(DDA) was €0.09 Mil.
Selling, General, & Admin. Expense(SGA) was €8.26 Mil.
Total Current Liabilities was €16.68 Mil.
Long-Term Debt & Capital Lease Obligation was €0.11 Mil.
Net Income was -2.224 + -1.536 + 2.402 + -109.877 = €-111.24 Mil.
Non Operating Income was 0.061 + 0.12 + 4.588 + -106.153 = €-101.38 Mil.
Cash Flow from Operations was -0.888 + -0.915 + -1.149 + -1.57 = €-4.52 Mil.
 Total Receivables was €1.01 Mil.
Revenue was 0 + 0 + 0 + 0 = €0.00 Mil.
Gross Profit was 0 + 0 + 0 + 0 = €0.00 Mil.
Total Current Assets was €3.39 Mil.
Total Assets was €108.90 Mil.
Property, Plant and Equipment(Net PPE) was €1.28 Mil.
Depreciation, Depletion and Amortization(DDA) was €0.12 Mil.
Selling, General, & Admin. Expense(SGA) was €17.49 Mil.
Total Current Liabilities was €26.68 Mil.
Long-Term Debt & Capital Lease Obligation was €0.46 Mil.

1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(0 / 0.018) / (1.009 / 0)
=0 /
=

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(0 / 0) / (0.018 / 0.018)
= / 1
=

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (3.229 + 0.011) / 8.53) / (1 - (3.393 + 1.281) / 108.897)
=0.620164 / 0.957079
=

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=0.018 / 0
=

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(0.119 / (0.119 + 1.281)) / (0.091 / (0.091 + 0.011))
=0.085 / 0.892157
=

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(8.26 / 0.018) / (17.485 / 0)
=458.888889 /
=

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((0.113 + 16.68) / 8.53) / ((0.461 + 26.679) / 108.897)
=1.968699 / 0.249226
=

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(-111.235 - -101.384 - -4.522) / 8.53
=-0.624736

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Frequently Asked Questions Learn more about Beneish M-Score →
What does a Beneish M-Score of 0.00 mean?
Lunai Bioworks (STU:2Q5) has a Beneish M-Score of 0.00 as of Jul. 29, 2026. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on Lunai Bioworks and its competitors. According to the industry distribution chart, Lunai Bioworks ranks #999999 out of 824 companies in the Biotechnology industry.
Is Lunai Bioworks' Beneish M-Score too high?
Lunai Bioworks' current Beneish M-Score is 0.00. Based on the distribution chart, Lunai Bioworks ranks #999999 out of 824 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Lunai Bioworks has a GF Score™ of 26/100, reflecting its overall financial health beyond just this single metric.
How does Lunai Bioworks' Beneish M-Score compare to BCLI and BIVI?
According to the Biotechnology industry distribution chart, Lunai Bioworks ranks #999999 out of 824 companies for Beneish M-Score. This places Lunai Bioworks in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beneish M-Score for a Biotechnology company?
A good Beneish M-Score depends on the Biotechnology industry context. However, Beneish M-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beneish M-Score mean?
A high Beneish M-Score can signal that a stock is expensive relative to its fundamentals. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on Lunai Bioworks and its competitors. Lunai Bioworks's current Beneish M-Score is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Lunai Bioworks stock overvalued right now?
Lunai Bioworks (STU:2Q5) has a current Beneish M-Score of 0.00. The current Beneish M-Score is 0.00. Lunai Bioworks' overall GF Score™ is 26/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beneish M-Score calculated?
Beneish M-Score is calculated from a company's financial statements. For Lunai Bioworks (STU:2Q5), the current Beneish M-Score is 0.00 as of Jul. 29, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Lunai Bioworks Business Description

Other Exchanges LNAI:USA
Address 2080 Century Park East, Suite 906, Los Angeles, CA, USA, 90067
Lunai Bioworks Inc is a biopharmaceutical company. Through its subsidiaries, it is mainly focused on developing allogeneic cell and gene therapies to promote stronger immune system responses, potentially for long-term or life-long cancer remission in some of the deadliest cancers. The group is engaged in the development of RENB-DC11 and RENB-DC20 (potential cell therapeutic vaccine candidates for different types of cancer); a proprietary AI platform that analyzes genetics to provide earlier and more accurate cancer diagnosis; and machine learning pipelines that harmonize and analyze complex, heterogeneous datasets to uncover clinically actionable insights. The group's reportable segments are: RENB, BioSymetrics, and RENC. Geographically, it operates in the United States and Netherlands.
26GF Score

Get the complete analysis for STU:2Q5

Beneish M-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€8.37
Price